Newsletter | August 27, 2026

08.27.26 -- What The FDA's Psychedelic Drug Focus Means For Classic Psychedelic Development

SPONSOR

Webinar: AI Reality Check in Drug Development: What’s Real and What’s Missing

AI is advancing drug discovery and development, but realizing its full potential depends on reliable, high-quality clinical data. Join Dr. Richard Graham, co-founder of TruTechnologies, and industry experts as they explore where AI is delivering value today, where challenges remain, and how sponsors can build the foundation for more effective AI-driven decisions across the drug development lifecycle. Click here to learn more.

OUTSOURCING MODELS

What Sponsors Value Most In CRO Partnerships

If your organization is uncertain about what truly separates strong research partnerships from disappointing ones, these data-driven findings can help you improve how you select, evaluate, and manage CRO partnerships.

How Many Vendors Does One Trial Really Need?

Operational friction can hinder trial performance. Discover how centralizing key functions improves coordination, lowers administrative burden, and enhances stakeholder experiences.

Full -Service Neuro-Science CRO

Explore how dedicated brain and nervous system research support, deep disease expertise, and operational rigor can optimize your clinical trial's success.

Who We Work With And What We Do For You

Explore an industry-first clinical trial execution system that delivers truly real-time visibility into trial execution at the point of care.

Speed, Precision, Impact: The CRO Revolutionizing Bioanalysis

Move drug development into the modern era with a CRO that offers assay development and validation, bioanalytical testing, sample prep, and more.

Accelerating Biologics Through Development Milestones

Whether you're aiming to run a pivotal trial or multiple studies, discover how Veristat's full-service support can drive your biologic therapies from inception to market success.

REGULATORY COMPLIANCE

What The FDA's Psychedelic Drug Focus Means For Classic Psychedelic Development

Complementing an interview with Enveric Bioscience's Joseph Tucker, Ph.D., this Q&A explores Josh Hardman's thoughts on what FDA’s psychedelic focus could mean for classic psychedelic development.

Who Decides? Navigating AI Governance in Clinical Research

AI in clinical research poses governance challenges. Clear ownership, consistent policies, and aligned teams help manage risk, ensure compliance, and drive responsible innovation in complex trials.

What UK Regulatory Changes Mean For Drug Developers And Sponsors

Stay ahead of the evolving UK regulatory landscape and leverage upcoming reforms to accelerate patient access, drive innovation, and strengthen your position in the medicines development market.

10 Clinical Research Practices That Feel Like Compliance (But Aren't)

Many clinical research routines are driven by habit, not regulation. This guide clears up 10 common misconceptions to streamline workflows and reduce unnecessary admin work.

Connect With Clinical Leader: